ID   SW1573/1R50
AC   CVCL_WG67
SY   SW-1573/1R50; SW-1573/50; SW1573/50; 1R50; 1R50b
DR   cancercelllines; CVCL_WG67
DR   Wikidata; Q98132914
RX   PubMed=1348862;
RX   PubMed=1353703;
RX   PubMed=1974823;
RX   PubMed=2566376;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C2923; Minimally invasive lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A5BA ! SW1573/S1
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 05-10-23; Version: 8
//
RX   PubMed=1348862; DOI=10.1073/pnas.89.8.3498; PMCID=PMC48895;
RA   Eijdems E.W.H.M., Borst P., Jongsma A.P.M., de Jong S.,
RA   de Vries E.G.E., van Groenigen M., Versantvoort C.H.M.,
RA   Nieuwint A.W.M., Baas F.;
RT   "Genetic transfer of non-P-glycoprotein-mediated multidrug resistance
RT   (MDR) in somatic cell fusion: dissection of a compound MDR
RT   phenotype.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3498-3502(1992).
//
RX   PubMed=1353703;
RA   Nieuwint A.W.M., Baas F., Wiegant J., Joenje H.;
RT   "Cytogenetic alterations associated with P-glycoprotein- and
RT   non-P-glycoprotein-mediated multidrug resistance in SW-1573 human lung
RT   tumor cell lines.";
RL   Cancer Res. 52:4361-4371(1992).
//
RX   PubMed=1974823;
RA   Baas F., Jongsma A.P.M., Broxterman H.J., Arceci R.J., Housman D.E.,
RA   Scheffer G.L., Riethorst A., van Groenigen M., Nieuwint A.W.M.,
RA   Joenje H.;
RT   "Non-P-glycoprotein mediated mechanism for multidrug resistance
RT   precedes P-glycoprotein expression during in vitro selection for
RT   doxorubicin resistance in a human lung cancer cell line.";
RL   Cancer Res. 50:5392-5398(1990).
//
RX   PubMed=2566376;
RA   Keizer H.G., Schuurhuis G.J., Broxterman H.J., Lankelma J.,
RA   Schoonen W.G.E.J., van Rijn J., Pinedo H.M., Joenje H.;
RT   "Correlation of multidrug resistance with decreased drug accumulation,
RT   altered subcellular drug distribution, and increased P-glycoprotein
RT   expression in cultured SW-1573 human lung tumor cells.";
RL   Cancer Res. 49:2988-2993(1989).
//